Novel non-antibiotic strategy against ogip infections based on an activated cereal product or ferric quinate

Abstract

The present invention refers to a non-antibiotic therapeutic strategy for inhibiting oro-gastro-intestinal infections and pathogens in general and particularly Heliobacter pylori adherence and colonization in the gastro-intestinal channel and preventing or relieving associated oro-gastro-intestinal disease. The invention relates to methods and products based on an active cereal product or ferric quinate. The invention is also applicable to other oro-gastro-intestinal pathogens in both humans and animals.

1 . A cereals fermenting microorganism, characterized by having the ability to provide, upon fermentation of the cereal, activated products derived from the cereal and being inhibitors of the adherence and colonization of oro-gastro-intestinal pathogens (OGIP) in humans and animals.  
     
     
         2 . The microorganism of  claim 1 , characterized in that the cereal is rye bran.  
     
     
         3 . The microorganism of  claim 2 , characterized by being selected from  Lactobacillus  species.  
     
     
         4 . The microorganism of  claim 3 , characterized by being selected from  Lactobacillus curvatus  strains.  
     
     
         5 . The microorganism of  claim 4 , characterized by being  Lactobacillus curvatus  strain Lb14 deposited at Deutsche Sammlung von Mikroorganismen und Zelikulturen (DSMZ) under accession number 13890.  
     
     
         6 . The microorganism of  claim 1 , characterized in producing, upon fermentation of the cereal, an activated cereal product against OGIP infections by  Helicobacter pylori, Candida albicans  and  Streptococcus mutans  in humans and  Escherichia coli  and  Clostridium perfringens  in domestic and pet animals.  
     
     
         7 . Fermented cereal product, characterized by being obtained by fermentation of a cereal with a microorganism of  claim 1  and being an inhibitor of the adherence and colonization of OGIP in humans and animals.  
     
     
         8 . The fermented cereal product of  claim 7 , characterized by being derived from rye bran.  
     
     
         9 . The fermentation product of  claim 8 , characterized by being the supernatant of the fermentation broth obtained by fermentation of rye bran with the  Lactobacillus curvatus  strain Lb 14 (DSMZ 13890).  
     
     
         10 - 14 . (canceled).  
     
     
         15 . A functional food product being useful for treatment of humans and animals suffering from OGIP infections, characterized by comprising the fermented cereal product of  claim 7  and/or ferric quinate and, optionally, other acceptable ingredients to form a palatable food product.  
     
     
         16 . The functional food product of  claim 15  for treatment of infections by  Helicobacter pylori, Candida albicans  and  Streptococcus mutans  in humans and infections by  Escherichia coli  and  Clostridium perfringens  in domestic and pet animals.  
     
     
         17 . The functional food product of  claim 16 , characterized by comprising the fermented cereal product and/or ferric quinate.  
     
     
         18 . The functional food product of  claim 15  being a beverage, bread or muesli.  
     
     
         19 . A method of preparing the fermented cereal product of  claim 7 , characterized by subjecting, under conditions suitable for providing fermentation products from the cereal being competetive inhibitors of the adherence and colonization of OGIP in humans and animals, the cereal to fermentation by a microorganism and collecting the product from the fermentation broth.  
     
     
         20 . The method of  claim 19 , characterized by subjecting rye bran to fermentation.  
     
     
         21 . The method of  claim 20 , characterized by subjecting rye bran to fermentation by a microorganism being selected from  Lactobacillus curvatus  strains.  
     
     
         22 . The method of  claim 21 , characterized by subjecting rye bran to fermentation by the  Lactobacillus curvatus  strain Lb 14 deposited at DSMZ under accession number 13890.  
     
     
         23 . The method of  claim 22 , characterized in that the collected product from the fermentation broth is the supernatant.  
     
     
         24 . Growth promoting feedstuff supplement for domestic animals, characterized by being or comprising the fermented cereal product of  claim 7  and/or ferric quinate.  
     
     
         25 . Pharmaceutical product based on purified extracts, or fraction of extracts, and/or ferric quinate, with the  H. pylori -Lewis b antigen binding inhibitory (blocking) activity as a marker for the activated inhibitor of  claim 7 , for treatment of humans suffering from OGIP-infections in humans and domestic animals.  
     
     
         26 . The pharmaceutical product of  claim 25  for treatment of  Helicobacter pylori, Candida albicans  and  Streptococcus mutans  infections in humans.  
     
     
         27 . The pharmaceutical product of  claim 25  for treatment of  Escherichia Coli  and  Clostridium perfringens  infections in domestic cattle, pig and poultry.  
     
     
         28 . The pharmaceutical product of  claim 25  in the form of a mouth rinse for treatment of dental caries, periodontal disease and oral malodor/halitosis.  
     
     
         29 . (canceled).